GSK analyst estimates
GSK (GSK) analyst ratings, the average price target and its range, and every firm's latest call.
GSK analyst ratings and price targets
| Date | Firm | Call | Target |
|---|---|---|---|
| Oct 29, 2026 | Jefferies | GSK downgraded to Hold from Buy at Jefferies | $55.90 |
| Sep 15, 2026 | Berenberg Bank | Berenberg Upgrades GlaxoSmithKline (GSK) to Buy | $60.00 |
| Oct 30, 2025 | CFRA | CFRA Upgrades GlaxoSmithKline (GSK) to Buy | $53.00 |
| Apr 15, 2025 | BNP Paribas | GSK initiated with a Neutral at BNP Paribas Exane | $35.25 |
| Jul 2, 2024 | Jefferies | GSK price target raised to $53 from $52.50 at Jefferies | $53.00 |
| Apr 11, 2024 | Guggenheim | Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields | $36.00 |
| Apr 11, 2024 | Morgan Stanley | Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks With Over 3% Dividend Yields | $85.00 |
- 7 firms rate GSK: 2 buy, 4 hold, 1 sell.
- The average price target is $57.95 from 2 analysts, from $55.90 to $60.00.
Updated 2026-11-02 17:13 UTC